About Celgene Corporation (NASDAQ:CELG)
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:CELG
- CUSIP: 15102010
- Web: www.celgene.com
Capitalization:- Market Cap: $108.63722 billion
- Outstanding Shares: 782,350,000
Average Prices:- 50 Day Moving Avg: $141.25
- 200 Day Moving Avg: $130.39
- 52 Week Range: $96.93 - $147.17
P/E:- Trailing P/E Ratio: 42.48
- Foreward P/E Ratio: 16.33
- P/E Growth: 0.86
Sales & Book Value:- Annual Revenue: $12.19 billion
- Price / Sales: 8.80
- Book Value: $10.80 per share
- Price / Book: 12.70
Profitability:- EBITDA: $4.83 billion
- Net Margins: 21.35%
- Return on Equity: 68.51%
- Return on Assets: 17.04%
Debt:- Debt-to-Equity Ratio: 1.63%
- Current Ratio: 4.05%
- Quick Ratio: 3.89%
Misc:- Average Volume: 3.63 million shs.
- Beta: 1.88
- Short Ratio: 2.63
Frequently Asked Questions for Celgene Corporation (NASDAQ:CELG)
What is Celgene Corporation's stock symbol?
Celgene Corporation trades on the NASDAQ under the ticker symbol "CELG."
When did Celgene Corporation's stock split? How did Celgene Corporation's stock split work?
Celgene Corporation's stock split before market open on Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly issued shares were payable to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene Corporation stock prior to the split would have 200 shares after the split.
How were Celgene Corporation's earnings last quarter?
Celgene Corporation (NASDAQ:CELG) posted its quarterly earnings data on Thursday, July, 27th. The company reported $1.82 EPS for the quarter, beating analysts' consensus estimates of $1.61 by $0.21. The firm earned $3.27 billion during the quarter, compared to the consensus estimate of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The company's quarterly revenue was up 18.7% compared to the same quarter last year. During the same period last year, the company earned $1.44 EPS. View Celgene Corporation's Earnings History.
When will Celgene Corporation make its next earnings announcement?
What guidance has Celgene Corporation issued on next quarter's earnings?
Celgene Corporation updated its FY17 earnings guidance on Thursday, July, 27th. The company provided earnings per share guidance of $7.25-7.35 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.29. The company issued revenue guidance of $13.0-13.4 billion, compared to the consensus revenue estimate of $13.19 billion.
Where is Celgene Corporation's stock going? Where will Celgene Corporation's stock price be in 2017?
25 equities research analysts have issued 12 month price objectives for Celgene Corporation's shares. Their forecasts range from $98.00 to $175.00. On average, they anticipate Celgene Corporation's stock price to reach $152.30 in the next year. View Analyst Ratings for Celgene Corporation.
What are analysts saying about Celgene Corporation stock?
Here are some recent quotes from research analysts about Celgene Corporation stock:
- 1. According to Zacks Investment Research, "Celgene’s Revlimid continued to outperform driven by further market share increases in newly diagnosed myeloma and the continued increase in treatment duration. Other key products – Pomalyst/Imnovid, Abraxane and Otezla – also performed well. The consecutive increase in annual earnings guidance is also a positive. Celgene continues to progress with its label expansion efforts and pipeline development with sNDA submission for Revlimid in newly diagnosed multiple myeloma targeted for first-quarter 2018. The approval of Idhifa in the U.S. for relapsed and/or refractory acute myeloid leukemia has further boosted the company’s portfolio. Moreover, shares of Celgene have outperformed the industry in the year so far. However, Celgene is highly dependent on Revlimid while foreign exchange headwinds are expected to continue while Abraxane sales are under competitive pressure." (10/18/2017)
- 2. Cann analysts commented, "Celgene announced that Idhifa (enasidenib/AG-221) was granted approval from FDA for the treatment of adult patients with relapsed or refractory AML with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA approved test. It was reported that FDA approval was based on the clinical data from an open-label, single-arm, multicenter, two-cohort clinical trial of adult patients with relapsed or refractory AML with an IDH2 mutation (Study AG221-C-001, NCT01915498). Idhifa was approved concurrently with the Abbott RealTime IDH2 companion diagnostic test, which is FDA-approved as an aid in identifying AML patients for treatment with Idhifa." (8/1/2017)
- 3. Cantor Fitzgerald analysts commented, "Acquisition of worldwide Rights to BeiGene,s (NASDAQ: BGNE, NC) excluding Asia, PD-1 inhibitor for solid tumors, BGB-A317, enhances CELG’s oncology portfolio and augments its immuno-oncology efforts." (7/6/2017)
Who are some of Celgene Corporation's key competitors?
Some companies that are related to Celgene Corporation include Pfizer (PFE), Novartis AG (NVS), Merck & Company (MRK), Amgen (AMGN), Novo Nordisk A/S (NVO), Sanofi (SNY), Bristol-Myers Squibb Company (BMY), GlaxoSmithKline PLC (GSK), Abbott Laboratories (ABT), Eli Lilly and Company (LLY), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHPG), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY) and Catalent (CTLT).
Who are Celgene Corporation's key executives?
Celgene Corporation's management team includes the folowing people:
- Robert J. Hugin, Executive Chairman of the Board
- Scott A. Smith, President, Chief Operating Officer
- Mark J. Alles, Chief Executive Officer, Director
- Peter N. Kellogg, Chief Financial Officer, Executive Vice President
- Terrie Curran, President, Global Inflammation & Immunology Franchise
- Michael F. Pehl, President, Hematology & Oncology
- Rupert J. Vessey, President - Research and Early Development
- Gerald F. Masoudi, Executive Vice President, General Counsel and Corporate Secretary
- Michael D. Casey, Lead Independent Director
- Michael W. Bonney, Director
Who owns Celgene Corporation stock?
Celgene Corporation's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Bridges Investment Management Inc. (0.02%), Bath Savings Trust Co (0.01%), Neville Rodie & Shaw Inc. (0.01%), Centre Asset Management LLC (0.01%), Eqis Capital Management Inc. (0.01%) and Bridges Investment Counsel Inc. (0.00%). Company insiders that own Celgene Corporation stock include Corp /De/ Celgene, Ernest Mario, Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Michael W Bonney, Richard W Barker, Robert J Hugin, Rupert Vessey and Terrie Curran. View Institutional Ownership Trends for Celgene Corporation.
Who sold Celgene Corporation stock? Who is selling Celgene Corporation stock?
Celgene Corporation's stock was sold by a variety of institutional investors in the last quarter, including Bridges Investment Counsel Inc., Private Asset Management Inc. and Indiana Trust & Investment Management CO. Company insiders that have sold Celgene Corporation stock in the last year include Ernest Mario, Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Robert J Hugin, Rupert Vessey and Terrie Curran. View Insider Buying and Selling for Celgene Corporation.
Who bought Celgene Corporation stock? Who is buying Celgene Corporation stock?
Celgene Corporation's stock was bought by a variety of institutional investors in the last quarter, including Centre Asset Management LLC, Eqis Capital Management Inc., Neville Rodie & Shaw Inc., Bath Savings Trust Co, Beacon Financial Group, Bridges Investment Management Inc. and Park National Corp OH. Company insiders that have bought Celgene Corporation stock in the last two years include Corp /De/ Celgene and Michael W Bonney. View Insider Buying and Selling for Celgene Corporation.
How do I buy Celgene Corporation stock?
Shares of Celgene Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Celgene Corporation's stock price today?
One share of Celgene Corporation stock can currently be purchased for approximately $137.17.
MarketBeat Community Rating for Celgene Corporation (NASDAQ CELG)MarketBeat's community ratings are surveys of what our community members think about Celgene Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Celgene Corporation (NASDAQ:CELG) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Sell Ratings, 3 Hold Ratings, 20 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.72) |
| Consensus Price Target: | $152.30 (11.03% upside) |
Consensus Price Target History for Celgene Corporation (NASDAQ:CELG)
Analysts' Ratings History for Celgene Corporation (NASDAQ:CELG)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 10/16/2017 | J P Morgan Chase & Co | Reiterated Rating | Buy | | N/A |  |
| 10/17/2017 | Sanford C. Bernstein | Initiated Coverage | Outperform | $162.00 | N/A | |
| 10/17/2017 | BMO Capital Markets | Boost Price Target | Positive | $160.00 -> $167.00 | N/A | |
| 10/16/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $160.00 | N/A | |
| 10/16/2017 | Cantor Fitzgerald | Set Price Target | Buy | $162.00 | N/A | |
| 10/13/2017 | Barclays PLC | Boost Price Target | Equal Weight | $135.00 -> $140.00 | N/A | |
| 10/5/2017 | Royal Bank Of Canada | Reiterated Rating | Buy | $173.00 | N/A | |
| 10/5/2017 | Morgan Stanley | Downgrade | Equal Weight -> Underweight | $120.00 | N/A | |
| 9/21/2017 | Robert W. Baird | Reiterated Rating | Buy | $162.00 | Low | |
| 9/15/2017 | Mizuho | Boost Price Target | Buy -> Buy | $134.00 -> $158.00 | Medium | |
| 9/13/2017 | Bank of America Corporation | Reiterated Rating | Buy | | Low | |
| 9/12/2017 | Cowen and Company | Reiterated Rating | Buy | $150.00 | Low | |
| 9/5/2017 | BTIG Research | Reiterated Rating | Neutral | | Low | |
| 8/9/2017 | Oppenheimer Holdings, Inc. | Reiterated Rating | Outperform | $175.00 | Medium | |
| 8/1/2017 | Cann | Reiterated Rating | Buy | $175.00 | Low | |
| 7/31/2017 | Argus | Upgrade | Hold -> Buy | $96.93 -> $160.00 | Low | |
| 7/28/2017 | Leerink Swann | Reiterated Rating | Outperform | $150.00 -> $160.00 | Low | |
| 7/27/2017 | Canaccord Genuity | Set Price Target | Buy | $156.00 | Low | |
| 7/28/2017 | Stifel Nicolaus | Initiated Coverage | Buy | $155.00 | Low | |
| 7/14/2017 | SunTrust Banks, Inc. | Reiterated Rating | Buy | $150.00 | Low | |
| 7/6/2017 | Credit Suisse Group | Set Price Target | Buy | $148.00 | Low | |
| 6/26/2017 | William Blair | Reiterated Rating | Outperform | | Low | |
| 5/17/2017 | Goldman Sachs Group, Inc. (The) | Reiterated Rating | Sell | $93.00 -> $98.00 | Low | |
| 1/8/2017 | Evercore ISI | Reiterated Rating | Buy | $135.00 | N/A | |
| 11/9/2016 | Standpoint Research | Downgrade | Buy -> Hold | | N/A | |
| 10/18/2016 | Piper Jaffray Companies | Reiterated Rating | Buy | | N/A | |
| 9/29/2016 | Citigroup Inc. | Boost Price Target | Buy | $124.00 -> $127.00 | N/A | |
| 7/6/2016 | JMP Securities | Reiterated Rating | Buy | $152.00 | N/A | |
| 4/28/2016 | Raymond James Financial, Inc. | Reiterated Rating | Buy | | N/A | |
| 1/22/2016 | Wells Fargo & Company | Reiterated Rating | Outperform | | N/A | |
| 12/18/2015 | Atlantic Securities | Initiated Coverage | Neutral -> Neutral | | N/A | |
(Data available from 10/19/2015 forward)
Earnings History for Celgene Corporation (NASDAQ:CELG)Earnings History by Quarter for Celgene Corporation (NASDAQ CELG)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/26/2017 | | $1.89 | | | | | N/A | |
| 7/27/2017 | 6/30/2017 | $1.61 | $1.82 | $3.23 billion | $3.27 billion | View | N/A | |
| 4/27/2017 | Q1 2017 | $1.47 | $1.68 | $3.04 billion | $2.96 billion | View | N/A | |
| 1/26/2017 | Q416 | $1.59 | $1.61 | $3.03 billion | $2.98 billion | View | N/A | |
| 10/27/2016 | Q316 | $1.31 | $1.58 | $2.84 billion | $2.98 billion | View | Listen | |
| 7/28/2016 | Q216 | $1.39 | $1.44 | $2.70 billion | $2.74 billion | View | Listen | |
| 4/28/2016 | Q116 | $1.29 | $1.32 | $2.59 billion | $2.51 billion | View | Listen | |
| 1/28/2016 | Q415 | $1.22 | $1.18 | $2.54 billion | $2.54 billion | View | Listen | |
| 11/5/2015 | Q315 | $1.09 | $1.23 | $2.40 billion | $2.33 billion | View | N/A | |
| 7/23/2015 | Q215 | $1.08 | $1.23 | $2.24 billion | $2.28 billion | View | Listen | |
| 4/30/2015 | Q115 | $0.93 | $0.95 | $2.11 billion | $2.08 billion | View | N/A | |
| 1/29/2015 | Q414 | $0.88 | $0.91 | $2.08 billion | $2.09 billion | View | N/A | |
| 10/23/2014 | Q314 | $0.82 | $0.97 | $1.96 billion | $1.96 billion | View | Listen | |
| 7/24/2014 | Q214 | $0.77 | $0.80 | $1.85 billion | $1.87 billion | View | N/A | |
| 4/24/2014 | Q114 | $1.65 | $1.67 | $1.77 billion | $1.71 billion | View | N/A | |
| 1/30/2014 | Q413 | $1.54 | $1.51 | $1.72 billion | $1.76 billion | View | Listen | |
| 10/24/2013 | Q313 | $1.54 | $1.56 | $1.64 billion | $1.67 billion | View | N/A | |
| 7/25/2013 | Q2 2013 | $1.44 | $1.52 | $1.54 billion | $1.56 billion | View | Listen | |
| 4/25/2013 | Q1 2013 | $1.35 | $1.37 | $1.47 billion | $1.43 billion | View | Listen | |
| 1/24/2013 | Q4 2012 | $1.31 | $1.32 | $1.45 billion | $1.42 billion | View | Listen | |
| 10/25/2012 | | $1.26 | $1.29 | | | View | N/A | |
| 7/26/2012 | | $1.19 | $1.22 | | | View | N/A | |
| 4/26/2012 | | $1.13 | $1.08 | | | View | N/A | |
| 1/26/2012 | | $1.06 | $1.05 | | | View | N/A | |
| 10/27/2011 | | $0.95 | $1.02 | | | View | N/A | |
| 7/28/2011 | | $0.85 | $0.89 | | | View | N/A | |
| 4/28/2011 | | $0.80 | $0.83 | | | View | N/A | |
| 1/27/2011 | | $0.73 | $0.73 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Celgene Corporation (NASDAQ:CELG)2017 EPS Consensus Estimate: $6.61
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | $1.44 | $1.46 | $1.45 |
| Q2 2017 | 3 | $1.61 | $1.68 | $1.64 |
| Q3 2017 | 3 | $1.68 | $1.81 | $1.73 |
| Q4 2017 | 3 | $1.72 | $1.84 | $1.78 |
(Data provided by Zacks Investment Research)
Dividend History for Celgene Corporation (NASDAQ:CELG)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Celgene Corporation (NASDAQ:CELG)Insider Ownership Percentage: 0.95%
Institutional Ownership Percentage: 79.24%
Insider Trades by Quarter for Celgene Corporation (NASDAQ:CELG)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/25/2017 | Terrie Curran | Insider | Sell | 1,727 | $143.89 | $248,498.03 | |
| 9/12/2017 | Gilla Kaplan | Director | Sell | 9,250 | $141.56 | $1,309,430.00 | |
| 9/5/2017 | Michael D Casey | Director | Sell | 9,250 | $139.03 | $1,286,027.50 | |
| 8/10/2017 | Ernest Mario | Director | Sell | 18,506 | $130.52 | $2,415,403.12 | |
| 8/2/2017 | Gilla Kaplan | Director | Sell | 7,500 | $134.52 | $1,008,900.00 | |
| 6/26/2017 | James J Loughlin | Director | Sell | 18,500 | $133.57 | $2,471,045.00 | |
| 6/22/2017 | Michael A Friedman | Director | Sell | 10,000 | $132.50 | $1,325,000.00 | |
| 6/22/2017 | Robert J Hugin | Insider | Sell | 175,970 | $134.14 | $23,604,615.80 | |
| 6/21/2017 | Michael D Casey | Director | Sell | 9,250 | $133.05 | $1,230,712.50 | |
| 6/19/2017 | Michael D. Casey | Director | Sell | 9,250 | $125.59 | $1,161,707.50 | |
| 6/15/2017 | Rupert Vessey | Insider | Sell | 4,785 | $120.18 | $575,061.30 | |
| 5/1/2017 | James J Loughlin | Director | Sell | 9,250 | $124.00 | $1,147,000.00 | |
| 3/30/2017 | Gilla Kaplan | Director | Sell | 14,033 | $123.83 | $1,737,706.39 | |
| 3/1/2017 | Rupert Vessey | Insider | Sell | 4,000 | $124.42 | $497,680.00 | |
| 11/9/2016 | Michael A Friedman | Director | Sell | 18,600 | $116.10 | $2,159,460.00 | |
| 10/24/2016 | Corp /De/ Celgene | Major Shareholder | Buy | 800,150 | $14.00 | $11,202,100.00 | |
| 10/3/2016 | Michael A Friedman | Director | Sell | 56,116 | $103.66 | $5,816,984.56 | |
| 9/23/2016 | Richard W Barker | Director | Sell | 20,000 | $110.82 | $2,216,400.00 | |
| 9/15/2016 | Gilla Kaplan | Director | Sell | 9,710 | $106.44 | $1,033,532.40 | |
| 8/23/2016 | James J Loughlin | Director | Sell | 27,500 | $114.10 | $3,137,750.00 | |
| 8/22/2016 | Michael D Casey | Director | Sell | 43,134 | $114.01 | $4,917,707.34 | |
| 7/28/2016 | Robert J Hugin | Insider | Sell | 100,000 | $110.00 | $11,000,000.00 | |
| 6/20/2016 | Robert J Hugin | Insider | Sell | 75,000 | $100.16 | $7,512,000.00 | |
| 4/4/2016 | Gilla Kaplan | Director | Sell | 15,967 | $101.84 | $1,626,079.28 | |
| 3/3/2016 | Michael W Bonney | Director | Buy | 2,000 | $103.01 | $206,020.00 | |
| 2/22/2016 | James J Loughlin | Director | Sell | 2,100 | $104.12 | $218,652.00 | |
| 12/28/2015 | Ernest Mario | Director | Sell | 40,000 | $119.36 | $4,774,400.00 | |
| 12/23/2015 | Michael D Casey | Director | Sell | 20,000 | $122.11 | $2,442,200.00 | |
| 12/21/2015 | Gilla Kaplan | Director | Sell | 14,464 | $110.62 | $1,600,007.68 | |
| 9/10/2015 | Gilla Kaplan | Director | Sell | 15,000 | $122.45 | $1,836,750.00 | |
| 9/8/2015 | Michael D. Casey | Director | Sell | 15,000 | $121.76 | $1,826,400.00 | |
| 7/13/2015 | Thomas O Daniel | Insider | Sell | 30,156 | $120.78 | $3,642,241.68 | |
| 6/10/2015 | Gilla Kaplan | Director | Sell | 15,000 | $111.74 | $1,676,100.00 | |
| 6/9/2015 | Michael D Casey | Director | Sell | 15,000 | $111.18 | $1,667,700.00 | |
| 2/26/2015 | Gilla Kaplan | Director | Sell | 15,000 | $122.89 | $1,843,350.00 | |
| 2/6/2015 | Mark J Alles | Insider | Sell | 117,099 | $120.68 | $14,131,507.32 | |
| 1/15/2015 | Lawrence V Stein | Insider | Sell | 26,666 | $120.01 | $3,200,186.66 | |
| 1/2/2015 | Gilla Kaplan | Director | Sell | 45,536 | $113.47 | $5,166,969.92 | |
| 12/8/2014 | Gilla Kaplan | Director | Sell | 15,000 | $118.20 | $1,773,000.00 | |
| 11/3/2014 | Robert J Hugin | Insider | Sell | 158,000 | $106.68 | $16,855,440.00 | |
| 10/27/2014 | Ernest Mario | Director | Sell | 100,000 | $102.85 | $10,285,000.00 | |
| 10/24/2014 | Michael D Casey | Director | Sell | 15,000 | $102.94 | $1,544,100.00 | |
| 9/8/2014 | Gilla Kaplan | Director | Sell | 30,000 | $93.73 | $2,811,900.00 | |
| 8/4/2014 | Perry A Karsen | Insider | Sell | 39,104 | $87.55 | $3,423,555.20 | |
| 7/25/2014 | Richard W Barker | Director | Sell | 17,600 | $87.03 | $1,531,728.00 | |
| 5/1/2014 | Perry Karsen | Insider | Sell | 11,922 | $146.78 | $1,749,911.16 | |
| 3/4/2014 | Michael Casey | Director | Sell | 12,770 | $162.33 | $2,072,954.10 | |
| 2/5/2014 | Ernest Mario | Director | Sell | 13,500 | $151.87 | $2,050,245.00 | |
| 12/23/2013 | Lawrence Stein | Insider | Sell | 12,062 | $168.19 | $2,028,707.78 | |
| 10/25/2013 | Carrie Smith Cox | Director | Sell | 18,750 | $157.67 | $2,956,312.50 | |
| 9/4/2013 | Gilla Kaplan | Director | Sell | 15,000 | $143.92 | $2,158,800.00 | |
| 8/28/2013 | Thomas Daniel | Insider | Sell | 32,263 | $137.06 | $4,421,966.78 | |
| 8/2/2013 | Perry A Karsen | Insider | Sell | 93,008 | $146.50 | $13,625,672.00 | |
| 5/30/2013 | Robert J Hugin | Insider | Sell | 68,087 | $123.58 | $8,414,191.46 | |
| 5/29/2013 | Ernest Mario | Director | Buy | 1,000 | $123.72 | $123,720.00 | |
| 5/28/2013 | Thomas O Daniel | Insider | Sell | 32,959 | $124.91 | $4,116,908.69 | |
(Data available from 1/1/2013 forward)
Headline Trends for Celgene Corporation (NASDAQ:CELG)
Latest Headlines for Celgene Corporation (NASDAQ:CELG)
| Source: |
|
| Date | Headline |
|---|
 | Celgene Corporation (CELG) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - October 19 at 1:44 AM |
| Zacks Investment Research Lowers Celgene Corporation (CELG) to Hold
www.americanbankingnews.com - October 18 at 10:20 PM |
 | Breakfast Technical Briefing on Biotech Stocks -- BioCryst Pharma, Celgene, Juno Therapeutics, and Lexicon Pharma
www.bizjournals.com - October 18 at 6:23 PM |
 | Top Stock Reports for IBM, Celgene and Procter & Gamble
finance.yahoo.com - October 18 at 6:23 PM |
| FY2017 EPS Estimates for Celgene Corporation Decreased by Analyst (CELG)
www.americanbankingnews.com - October 18 at 9:56 AM |
| Zacks: Analysts Expect Celgene Corporation (CELG) to Post $1.88 EPS
www.americanbankingnews.com - October 18 at 12:12 AM |
 | Notable ETF Outflow Detected - XLV, JNJ, PFE, CELG
www.nasdaq.com - October 17 at 5:51 PM |
| Top 3 Healthcare Stocks for 2017
finance.yahoo.com - October 17 at 5:51 PM |
| Celgene Corporation (CELG) PT Raised to $167.00
www.americanbankingnews.com - October 17 at 8:30 AM |
| Leerink Swann Weighs in on Celgene Corporation's Q3 2017 Earnings (CELG)
www.americanbankingnews.com - October 17 at 7:34 AM |
 | Celgene’s (CELG) Upgraded to Buy
investorplace.com - October 16 at 5:50 PM |
| Celgene Blood Cancer Treatment: Just The Tip Of Its Disruptive Science?
finance.yahoo.com - October 16 at 5:50 PM |
| Results from Phase 2 Studies of Oral Ozanimod in Crohn’s Disease and Ulcerative Colitis to Be Presented at World Congress of Gastroenterology at ACG2017
finance.yahoo.com - October 16 at 5:50 PM |
| Today's Research Reports on Stocks to Watch: Celgene Corporation and Valeant Pharmaceuticals
finance.yahoo.com - October 16 at 5:50 PM |
| Celgene Corp. breached its 50 day moving average in a Bearish Manner : CELG-US : October 16, 2017
finance.yahoo.com - October 16 at 5:50 PM |
| ETFs with exposure to Celgene Corp. : October 16, 2017
finance.yahoo.com - October 16 at 5:50 PM |
| Jefferies Group LLC Reaffirms Buy Rating for Celgene Corporation (CELG)
www.americanbankingnews.com - October 16 at 5:26 PM |
| Celgene’s (CELG) Upgraded to Buy
investorplace.com - October 16 at 2:34 PM |
 | Former Grant & Eisenhofer lawyer says he didn't poach Celgene whistleblower
www.reuters.com - October 13 at 10:45 PM |
| Celgene Corporation (CELG) PT Raised to $140.00
www.americanbankingnews.com - October 13 at 7:02 PM |
| Valeant Reports Positive Results on Psoriasis Drug Siliq
finance.yahoo.com - October 13 at 5:42 PM |
| MannKind Tripled In The Past 3 Weeks; Vindicating Nate Pile
finance.yahoo.com - October 10 at 6:16 PM |
| Mallinckrodt to Begin Sarcoidosis Study on Acthar Gel
finance.yahoo.com - October 10 at 6:16 PM |
| Celgene (CELG) Stock Upgraded to Buy from a Hold
investorplace.com - October 9 at 1:09 PM |
| Celgene Corporation Target of Unusually Large Options Trading (CELG)
www.americanbankingnews.com - October 8 at 1:40 AM |
| Celgene Corporation Sees Unusually High Options Volume (CELG)
www.americanbankingnews.com - October 8 at 1:40 AM |
| Celgene Corporation (CELG) Upgraded to Buy at Vetr Inc.
www.americanbankingnews.com - October 7 at 11:14 PM |
 | Better Buy: Celgene Corporation vs. Bristol-Myers Squibb - Motley Fool
www.fool.com - October 7 at 10:33 PM |
| This Dirt-Cheap Biotech Stock Is a Bargain to Buy
finance.yahoo.com - October 7 at 5:30 PM |
| Better Buy: Celgene Corporation vs. Bristol-Myers Squibb
www.fool.com - October 7 at 10:54 AM |
 | Mike Khouw Sees Unusual Options Activity In Celgene - Benzinga
www.benzinga.com - October 6 at 10:18 PM |
| Should You Sell Celgene Stock Following an Analyst Downgrade ... - Motley Fool
www.fool.com - October 6 at 10:18 PM |
| No Side Effects to This Bullish Trade on Celgene Corporation (CELG) Stock - Investorplace.com
investorplace.com - October 6 at 10:18 PM |
| Cramer Remix: Don’t ignore the oldest rule in the game wh...
finance.yahoo.com - October 6 at 10:18 PM |
 | Cramer Remix: Don’t ignore the oldest rule in the game when it comes to Celgene
www.cnbc.com - October 6 at 8:16 PM |
| No Side Effects to This Bullish Trade on Celgene Corporation (CELG) Stock
investorplace.com - October 6 at 9:54 AM |
 | Celgene Corp. (CELG) Is Losing Ground Following Downgrade
www.rttnews.com - October 6 at 2:11 AM |
| As Celgene Outperforms, Are Challenges To Its Pipeline Being Overlooked?
finance.yahoo.com - October 5 at 9:09 PM |
| Should You Sell Celgene Stock Following an Analyst Downgrade?
finance.yahoo.com - October 5 at 9:09 PM |
| Morgan Stanley Lowers Celgene Corporation (CELG) to Underweight
www.americanbankingnews.com - October 5 at 8:56 PM |
| Celgene Is Not a Sell, Jim Cramer Rebuts Analysts' Call
finance.yahoo.com - October 5 at 4:07 PM |
| Celgene Corporation (CELG) Receives Buy Rating from Royal Bank Of Canada
www.americanbankingnews.com - October 5 at 1:32 PM |
| Celgene Corp. (CELG) Is Losing Ground Following Downgrade - Nasdaq
www.nasdaq.com - October 5 at 11:38 AM |
| 3 Big Pharma Stocks Set to Succeed
finance.yahoo.com - October 5 at 11:38 AM |
| Which Stocks May Outperform in the Next Market Crash
finance.yahoo.com - October 5 at 11:38 AM |
| Morning Movers: Constellation Brands Jumps, Biogen Bounces, Celgene Slips
finance.yahoo.com - October 5 at 11:38 AM |
| Cramer's Stop Trading: Celgene is not a sell
finance.yahoo.com - October 5 at 11:38 AM |
| Celgene Corporation (CELG) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - October 4 at 5:20 PM |
 | Nimbus Therapeutics and Celgene Enter Long-Term Strategic ... - Business Wire (press release)
www.businesswire.com - October 4 at 12:24 PM |
 | Nimbus Therapeutics Announces Strategic Immunology Alliance ... - StreetInsider.com
www.streetinsider.com - October 3 at 4:56 PM |
Celgene Corporation (CELG) Chart for Thursday, October, 19, 2017
